OCI 2 3.20 Febru PTO/SB/08B (Modified)

Information Disclosure Statement By Applicant

(Use Several Sheets if Necessary)

Atty Docket No.:	Application No.:	
SHE0064.00	10/659,735	
Applicant:		
Anton	i KOZLOWSKI	
Filing Date:	Group:	

Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
BF	A	NEKTAR™ - Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, pp. 1-20, (Catalog – 2003).
BF	В	NOF CORPORATION, "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals", pp. 1-46, (Catalogue 2003-151).
BF	С	NOF CORPORATION, "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals", pp. 1-50, (Catalogue 2003-2 nd).
BF	D	SHEARWATER POLYMERS, INC., p. 2-49, (Catalog - March, 1995).
BF	E	SHEARWATER POLYMERS, INC., Polyethylene Glycol and Derivatives, pp. 1-53, (Catalog – July, 1997).
BF	F	SHEARWATER POLYMERS, INC., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, pp. 1-50, (Catalog - 2000).
BF	G	SHEARWATER CORPORATION, Polyethylene Glycol and Derivatives for Biomedical Applications, pp.1-17, (Catalog – 2001).
	_	
	 	
Examiner:	/Blessing F	Date Considered: 12/31/2006

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.